Variants in BRCA1 and BRCA2 disrupt the HRR pathway, compromising the ability of cancer cells to repair platinum-induced DNA damage and thereby increasing their sensitivity to platinum-based chemotherapy. This evidence concerns the gene BRCA2 and cancer.